Canada increases order for Moderna's COVID-19 vaccine
The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses, bringing the total order commitment to 40 million doses. Read More
Tevard Biosciences, Zogenix partner on tRNA-based gene therapies
Tevard Biosciences and Zogenix are joining forces to identify and develop novel transfer RNA (tRNA)-based gene therapies for Dravet syndrome and other genetic epilepsies. Read More
Moderna's COVID-19 vaccine demonstrates durable immunity in early clinical trial
Moderna published interim data from a National Institutes of Health-led phase I study of its messenger RNA (mRNA)-1273 COVID-19 vaccine on December 3 in the New England Journal of Medicine that shows durable immunity. Read More
I-Mab advances cancer monoclonal antibody to late-stage clinical trials
I-Mab is advancing the clinical development of lemzoparlimab in the U.S. and China for the treatment of non-Hodgkin lymphoma and advanced solid tumors. Read More
Takeda to distribute Y-mAbs' cancer antibody treatment in Israel
Y-mAbs and Takeda Israel, a subsidiary of Takeda Pharmaceutical, have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of naxitamab-gqgk (Danyelza) and omburtamab. Read More
Magenta Therapeutics, Bluebird Bio to test stem cell mobilization combo in clinic
Magenta Therapeutics and Bluebird Bio have entered an exclusive clinical trial collaboration to evaluate MGTA-145, Magenta's chemokine receptor, in combination with plerixafor, an immunostimulant, for mobilization and collection of stem cells in patients with sickle cell disease. Read More
Merck KGaA, Artios partner on DNA damage response drugs
Artios Pharma and Merck KGaA are set to develop multiple cancer drugs aimed at DNA damage response pathways through a new three-year long research and development partnership. Read More
Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800, which is in phase II/III development. Read More
Abveris, Saccharo partner on antibody discovery
Abveris has entered into an antibody discovery partnership with Saccharo for the discovery of monoclonal antibodies to advance Saccharo's immuno-oncology therapeutic pipeline. Read More
GEMoaB begins UniCAR-T PSMA clinical trial for solid tumors
GEMoaB has initiated its phase IA clinical trial with UniCAR-T prostate-specific membrane antigen (PSMA), an investigational UniCAR cellular immunotherapy, for the treatment of relapsed/refractory solid tumors expressing PSMA. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
